Myomo, INC Form 4 insider transactions

Chief Medical Officer Harry Kovelman reduced his stake in Myomo, Inc. through open market sales totaling 32,000 shares over two days.

Director Thomas F. Kirk acquired 75,006 shares of Myomo, Inc. common stock through open market purchases.

Joseph M. Manko Jr., a Director at MYOMO, INC., has reported transactions involving the acquisition of company stock.

Myomo, Inc. Chief Commercial Officer Micah Mitchell sold 90,231 shares of common stock in open market transactions.

Director William J. Febbo was granted 45,000 restricted stock units in Myomo, Inc. vesting on the first anniversary of the grant.

Myomo CEO Paul Gudonis received 16,666 restricted stock units as part of a voluntary program to exchange 10% of his salary for equity at a premium.

Myomo, Inc. Chief Financial Officer David A. Henry received a grant of Restricted Stock Units and subsequently sold shares to cover tax obligations.

Myomo, Inc. CEO Paul R. Gudonis received a grant of 19,395 Restricted Stock Units (RSUs) valued at 115% of foregone salary.

MYOMO, Inc. Director Heather C. Getz has pre-arranged to purchase 20,000 shares of common stock under a Rule 10b5-1 plan.

MYOMO, Inc. Director Thomas F. Kirk acquired 72,000 shares of common stock in an open market transaction on March 13, 2026.

Myomo, Inc. Director Heather C. Getz acquired 70,000 shares of common stock at an average price of $0.728 per share on March 12, 2026.

MYOMO, Inc. CEO Paul R. Gudonis acquired 11,637 Restricted Stock Units as part of a salary exchange program, vesting on April 12, 2026.

MYOMO's Chief Financial Officer, David A. Henry, acquired 8,727 Restricted Stock Units on January 12, 2026, as part of a company-approved salary exchange program.

MYOMO, Inc. Director Thomas F. Kirk acquired 7,437 shares of common stock through open market purchases on November 20 and 21, 2025, at $0.72 per share.

MYOMO Director Thomas Crowley Jr. reported open market purchases of common stock totaling 4,385 shares on November 18 and 19, 2025.

MYOMO, Inc. CEO Paul R. Gudonis reported gifting 10,000 shares of common stock to a third party on September 9, 2025.

MYOMO Director Thomas F. Kirk acquired 50,000 shares of common stock at $1.15 per share, increasing his direct beneficial ownership.

Myomo Director Thomas F. Kirk purchased 50,000 shares of common stock at $1.10 per share, increasing his beneficial ownership.

MYOMO, Inc. CEO Paul R. Gudonis purchased 50,000 shares of common stock at an average price of $0.9459.

MYOMO, Inc.'s Chief Medical Officer, Harry Kovelman, sold 13,054 shares of common stock at $2.19 per share on June 30, 2025, to cover income taxes related to the vesting of restricted stock units.

Myomo, Inc.'s Chief Financial Officer, David A. Henry, sold 23,587 shares of common stock on June 30, 2025, at $2.19 per share, solely to cover income taxes related to the vesting of restricted stock units.

MYOMO, Inc. has reported that its Chief Medical Officer, Harry Kovelman, was granted 62,938 Restricted Stock Units (RSUs) under the company's 2018 Stock Option and Incentive Plan.

Myomo, Inc.'s Chief Commercial Officer, Micah Mitchell, was granted 59,440 Restricted Stock Units (RSUs) on June 11, 2025, as part of the company's 2018 Stock Option and Incentive Plan.

Myomo, Inc.'s Chief Financial Officer, David A. Henry, was granted 76,398 Restricted Stock Units (RSUs) as part of the company's 2018 Stock Option and Incentive Plan.

MYOMO, Inc. Chief Executive Officer and Director Paul R. Gudonis was granted 157,342 Restricted Stock Units (RSUs) as part of the company's 2018 Stock Option and Incentive Plan.

MYOMO, Inc. Director Thomas F. Kirk was granted 29,720 Restricted Stock Units (RSUs) under the company's 2018 Stock Option and Incentive Plan, aligning his interests with shareholders.

Myomo, Inc. Director Thomas Aloysius Crowley Jr. was granted 29,720 Restricted Stock Units (RSUs) under the company's 2018 Stock Option and Incentive Plan, vesting quarterly starting September 11, 2025.

Myomo, Inc. Director and 10% owner Milton Morris was granted 29,720 Restricted Stock Units (RSUs) on June 11, 2025, which will vest in quarterly installments starting September 11, 2025.

Myomo, Inc. Director Heather C. Getz was granted 29,720 Restricted Stock Units (RSUs) on June 11, 2025, as part of the company's 2018 Stock Option and Incentive Plan.

Myomo, Inc.'s Chief Medical Officer, Harry Kovelman, sold 5,743 shares of common stock on June 6, 2025, at $2.97 per share, solely to satisfy tax withholding requirements related to the vesting of restricted stock units.